Hints and tips:
...“We delivered on our commitment to separate the Specialty Chemicals business and did so ahead of schedule.”...
...Last month Carlyle, the Washington-based private equity group, won a fiercely competitive auction to take over Akzo Nobel’s €10.1bn specialty chemicals unit after the business became a takeover target....
...Carlyle wins fight for Akzo Nobel speciality chemicals arm A group of investors led by US buyout giant Carlyle agreed to pay €10.1bn including debt for Akzo Nobel’s specialty chemicals unit after months...
...AkzoNobel has also put its specialty chemicals unit up for sale, and Sanofi is selling a drug unit. Both auctions have attracted interest from private equity....
...Already the auction of Akzo Nobel’s €8bn-€12bn specialty chemicals division has attracted fierce competition from private equity firms clubbing together, including one group consisting of Advent International...
...Ulta started the year on the front foot, particularly as it and other specialty beauty chains like Sephora seemed better poised to weather the general malaise that has beset other brick-and-mortar retailers...
...Smart Reads Patent shadow A trio of pharma groups — Teva Pharmaceuticals, Mylan and Akorn — are trying to have Allergan’s intellectual property invalidated so they can launch cheaper copycat versions of...
...While athleisure, the moniker used for a trend which sees people wear work out gear outside of the gym, had helped certain sports retailers buck some of the broader retail pain, specialty sports retailers...
...Four of the eight specialty pharma stocks in his merger arbitrage fund are in the red for 2017, although the two largest holdings, Mylan and Allergan, are up by double-digit percentages, meaning the pharma...
...Notable acquisitions for the quarter included Atotech, a specialty chemical business and Golden Goose, the Italian fashion brand. It sold its remaining stake in NT Butterfield & Son....
...., a US specialty generic pharmaceutical company, concerning a potential acquisition of Akorn, Inc. Akorn, Inc. shares are listed on the NASDAQ Global Select Market....
...Can companies such as Mylan, Teva and Hikma stop the bleeding?...
...The move arrives amid turmoil in the specialty sports retailers space as consumers increasingly shop online and buy directly from brands like Nike and Under Armour....
...That no analyst thought to title their note “Potholes in Mylan” only underlines what a clunker of a year it’s been....
...France’s Total has struck a $3.2bn deal to sell its Atotech specialty chemicals business to private equity heavyweight Carlyle Group as European energy majors look to sell off non-core assets to shore up...
...David Meeker, head of the Genzyme specialty care business, a Sanofi subsidiary, said last month that rare disease assets were among the potential targets for the company as it eyes growth opportunities....
...Proteostasis, a specialty pharmaceutical company that focuses on solving an issue with protein folding that can contribute to a range of diseases, priced its initial public offering at $8 a share....
...The fund was a so-called “permanent capital” vehicle created to supplement his private hedge fund Pershing Square LP, which returned nearly 800 per cent between 2004 and 2014....
...around 10 per cent of the overall market and 25 per cent of the subprime market, offered some re-assurance that net charge offs (when the debt is written off) were still tracking historical averages, with specialty...
...Wall Street generated $1.1bn in investment banking fees supporting the deal sprees behind Valeant, Altice, Platform Specialty and Nomad, according to estimates from Thomson Reuters and Freeman Consulting...
...A successful bid for Mylan would allow Teva, the world’s largest generic drugmaker, to create a company with annual revenues of more than $30bn and establish a leading position in the “specialty” drugs market...
...It has faced scrutiny for its relationship with specialty pharmacies such as Philidor Rx, with which it cut ties in late October....
...Thoughts have turned to Valeant’s cash flow once ties to Philidor, a controversial specialty pharmacy responsible for 6 per cent of sales in the first 9 months of this year, are severed....
...If combined, over 40 per cent of Teva-Mylan’s revenues would come from so-called “specialty” drugs rather than low-margin copycat pills, underscoring the trend of generic makers moving into more profitable...
...He has also been active this year in other M&A activity, including pushing for a combination of drug companies Mylan and Perrigo. Paulson & Co did not elaborate on its intentions with Starwood....
International Edition